0051 Samelisant, a H3 Receptor Inverse Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease
Sign Up to like & getrecommendations! Published in 2023 at "SLEEP"
DOI: 10.1093/sleep/zsad077.0051
Abstract: Samelisant (SUVN-G3031) is a potent and selective histamine 3 receptor (H3R) inverse agonist with hH3 Ki of 8.7 nM. Samelisant exhibited desired pharmacokinetic properties and favorable brain penetration in rodents. Preclinical studies demonstrated samelisant produced… read more here.
Keywords: samelisant; daytime sleepiness; excessive daytime; treatment ... See more keywords